Tuladhar L R, Tamrakar Tuladhar E T
Department of Pharmacology, Nepal Medical College, Kathmandu, Nepal.
Department of Biochemistry, Tribhuvan University Teaching Hospital, Institute of Medicine (IOM), Maharajgunj, Kathmandu, Nepal.
Kathmandu Univ Med J (KUMJ). 2017;15(60):279-283.
Background Salbutamol is a short acting β2 agonist bronchodilator most commonly used for management of asthma and chronic obstructive pulmonary disease. Besides the disease state, it is also used for bronchodilator reversibility in spirometry. The spirometry reading show one of the four patterns i.e. normal, obstructive, restrictive and combined or mixed (obstructive-restrictive). Objective To determine the efficacy of salbutamol in mixed obstructive and restrictive pattern spirometry. Method A descriptive cross sectional study was conducted at Nepal Medical College and Teaching Hospital (NMCTH) for a period of 9 months. A total of 70 patients who presented with symptoms of respiratory disease in medicine outpatient department (OPD) in which spirometry was performed were selected. Of the 70 patients, 35 with mixed pattern spirometry were selected as cases and remaining 35 with normal spirometry were selected as control. After taking informed consent, spirometry parameter were measured before and after salbutamol therapy. Data was collected from medicine department, pulmonary function test (PFT) unit. All the data were entered in statistical package for social sciences (SPSS version 20) and Forced expiratory volume in first second (FEV1 ), Forced vital capacity (FVC), FEV1 /FVC and Peak expiratory flow rate (PEFR) were analyzed. Result There was significant difference (p<0.05) in spirometry parameters (i.e. FEV1 , FVC, PEFR) when after salbutamol therapy was compared from before therapy. Statistical significance was also seen in percentage change in spirometry parameter (i.e. %FEV1 change, %FVC change, % change in ratio of FEV1 /FVC and %PEFR change) between case and control groups. Conclusion Salbutamol is an effective bronchodilator in mixed pattern or combined obstructiverestrictive lung disease.
沙丁胺醇是一种短效β2受体激动剂支气管扩张剂,最常用于治疗哮喘和慢性阻塞性肺疾病。除了疾病状态外,它还用于肺活量测定中的支气管扩张剂可逆性测试。肺活量测定结果显示四种模式之一,即正常、阻塞性、限制性和混合性(阻塞性-限制性)。
确定沙丁胺醇在混合性阻塞性和限制性模式肺活量测定中的疗效。
在尼泊尔医学院和教学医院(NMCTH)进行了为期9个月的描述性横断面研究。总共选择了70名在医学门诊(OPD)出现呼吸道疾病症状并进行了肺活量测定的患者。在这70名患者中,35名肺活量测定为混合模式的患者被选为病例组,其余35名肺活量测定正常的患者被选为对照组。在获得知情同意后,在沙丁胺醇治疗前后测量肺活量测定参数。数据从医学科、肺功能测试(PFT)单元收集。所有数据都输入到社会科学统计软件包(SPSS 20版)中,并对第一秒用力呼气量(FEV1)、用力肺活量(FVC)、FEV1/FVC和呼气峰值流速(PEFR)进行分析。
与治疗前相比,沙丁胺醇治疗后肺活量测定参数(即FEV1, FVC, PEFR)有显著差异(p<0.05)。病例组和对照组之间肺活量测定参数的百分比变化(即%FEV1变化、%FVC变化、FEV1/FVC比值变化百分比和%PEFR变化)也具有统计学意义。
沙丁胺醇在混合模式或合并阻塞性-限制性肺部疾病中是一种有效的支气管扩张剂。